PeptiDream Announces Initiation of Phase 1 Clinical Trial by MSD
Filed with TSE · · 2 pages · English
Summary by 6ix AI
This milestone triggers an undisclosed payment to PeptiDream, which will be recognized in the fourth quarter of the fiscal year. The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers for potential treatment of inflammatory diseases. PeptiDream's CEO expressed excitement about the collaboration with MSD and the progress of their peptide discovery efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
- Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
- PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
- PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
Earlier from PeptiDream
- PeptiDream Announces Achievement of Development Milestone in Collaboration with MSD
- Consolidated Financial Results for the Six Months Ended June 30, 2026 [IFRS]
- Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
- PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
Follow PeptiDream into a list and get an email when it puts out news.
Follow PeptiDream